Cidara Therapeutics Inc. (CDTX)
NASDAQ: CDTX
· Real-Time Price · USD
90.50
5.74 (6.77%)
At close: Sep 26, 2025, 3:59 PM
90.50
0.01%
After-hours: Sep 26, 2025, 07:32 PM EDT
Cidara Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2023 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|
| Collaboration Revenue Revenue | 7.61M | 32.86M | 2.41M |
| Collaboration Revenue Revenue Growth | -76.83% | +1264.74% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 6.5M | 6.18M | 7.31M | 4.96M | 4.69M | 6M | 7.17M | 3.56M | 3.31M | 4.46M | 3.43M | 5.78M | 4.07M | 5.2M | 4.98M | 4.61M | 4.37M | 4.78M | 4.15M | 3.69M | 3.97M | 4.09M | 4.41M | 4.57M | 3.52M | 3.73M | 3.55M | 3.45M | 3.53M | 3.61M | 3.23M | 3.09M | 3.42M | 3.15M | 3.04M | 3.61M | 3.39M | 2.7M | 2.36M | 2.44M | 2.24M | 1.8M |
| Selling, General, and Administrative Revenue Growth | +5.23% | -15.45% | +47.19% | +5.89% | -21.82% | -16.33% | +101.60% | +7.43% | -25.73% | +30.02% | -40.69% | +41.88% | -21.71% | +4.46% | +8.14% | +5.42% | -8.60% | +15.26% | +12.50% | -7.11% | -3.08% | -7.04% | -3.67% | +29.73% | -5.62% | +5.15% | +3.05% | -2.43% | -2.16% | +11.83% | +4.50% | -9.75% | +8.53% | +3.68% | -15.64% | +6.37% | +25.78% | +14.04% | -3.15% | +9.17% | +24.43% | n/a |
| Research and Development Revenue | 24.82M | 24.6M | 46.87M | 12.43M | 6.66M | 11.59M | 15.35M | 17.33M | 17.14M | 18.87M | 20.06M | 20.04M | 15.26M | 20.17M | 19.01M | 20.5M | 17.72M | 15.85M | 21.13M | 16.26M | 17.63M | 13M | 11.49M | 11.5M | 10.74M | 12.67M | 13.05M | 11.28M | 11.62M | 13.2M | 10.23M | 9.16M | 13.19M | 10.24M | 11.31M | 8.73M | 8.47M | 7.19M | 7.56M | 6.77M | 4.21M | 4.93M |
| Research and Development Revenue Growth | +0.88% | -47.52% | +277.13% | +86.71% | -42.58% | -24.49% | -11.41% | +1.14% | -9.19% | -5.93% | +0.08% | +31.37% | -24.35% | +6.06% | -7.28% | +15.72% | +11.81% | -24.99% | +29.96% | -7.80% | +35.69% | +13.11% | -0.08% | +7.04% | -15.20% | -2.89% | +15.68% | -2.93% | -11.97% | +29.02% | +11.69% | -30.57% | +28.78% | -9.43% | +29.57% | +3.05% | +17.83% | -4.96% | +11.79% | +60.71% | -14.69% | n/a |